Goodsurance

Drug prices & Part D

CMS Proposes a Sharp Cut to What Medicare Pays Hospitals for Drugs Bought Through the 340B Discount Program

A July 2 proposed rule would drop Medicare reimbursement for 340B-acquired drugs by nearly 40 percentage points, which CMS says could reduce what beneficiaries pay out of pocket for outpatient infusion drugs.

By the Goodsurance editorial teamJuly 10, 2026

On July 2, 2026, CMS issued a proposed rule for 2027 hospital outpatient payments that would significantly change how Medicare reimburses hospitals for prescription drugs purchased through the 340B Drug Pricing Program. Under that program, created by Congress in 1992, drug manufacturers must sell certain medications to qualifying hospitals and clinics at steep discounts. Currently, Medicare reimburses hospitals for those drugs at the drug's average sales price plus 6 percent. The proposed rule would cut that rate to average sales price minus 33.4 percent, a shift of nearly 40 percentage points. CMS cited a survey of hospital acquisition costs conducted between January and April 2026 showing that 340B hospitals pay substantially less for those drugs than the current Medicare payment implies. Because Medicare beneficiaries owe a share of the Medicare reimbursement rate as their copay for Part B drugs administered in hospital outpatient settings, a lower reimbursement rate would reduce patient out-of-pocket costs for treatments such as infusion therapies and certain cancer medications. CMS designed the proposal to be budget neutral, meaning projected savings from lower drug payments would be redistributed to higher reimbursements for other hospital outpatient services. Comments on the proposed rule are due August 31, 2026.

CMS proposed cutting Medicare's 340B hospital drug reimbursement by nearly 40 percentage points in 2027, a change that could reduce patient copays for outpatient infusion drugs.

In plain words

Some hospitals buy medicines at very low prices through a federal program called 340B. Medicare has been reimbursing those hospitals at a higher rate than what they paid for the drugs. On July 2, CMS proposed changing that for 2027 by paying much less. This would also lower the share patients pay out of pocket when they get certain drugs at hospital clinics. The money saved on drugs would shift to paying hospitals more for other services. Comments are due August 31.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

CMS Must Send Final Written Price Offers to 15 Drug Makers by September 30 in Third Negotiation Cycle

The final statutory step before drug manufacturers accept or reject Medicare prices arrives this week. CMS must issue written maximum fair price offers by September 30, and manufacturers have until October 31 to respond. Agreed prices would take effect in 2028.

September 23, 2026

Drug prices & Part D

About 140,000 Wellcare Part D Members Were Dropped Mid-Year After Small New Premiums Were Added to Their Previously Free Plans

KFF Health News found that Wellcare terminated tens of thousands of drug plan members in April 2026 when minimal monthly premiums went unpaid, leaving many without prescription coverage and at risk for permanent Medicare drug enrollment penalties.

September 21, 2026

Drug prices & Part D

MedPAC September Meeting Finds IRA Changes Improved Drug Affordability for Enrollees but May Be Accelerating Overall Medicare Part D Spending

Medicare's congressional advisory commission opened its new study cycle in September finding that Inflation Reduction Act drug benefit changes have helped individual beneficiaries while putting upward pressure on total program spending and future premiums.

September 20, 2026

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

September 19, 2026

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026

Drug prices & Part D

Federal Subsidy That Has Held Down Standalone Medicare Drug Plan Premiums for Two Years Is Ending After 2026

CMS is closing the Part D Premium Stabilization Demonstration after 2026, and a KFF analysis warns that people with standalone prescription drug plans in traditional Medicare could face larger premium increases in 2027 than they have seen in recent years.

September 13, 2026